A neural network (16) operating on volume data and using convolutional layers (24) may better classify conversion or Alzheimer's disease. The neural network (16) may be trained to operate on incomplete data. The neural network (16) may have a branching architecture (30-34) for more accurate classification given a variety of types of available data (20, 21) for a given patient.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride and a chelating group wherein either the fluorine is 18F or the chelating group contains a chelated radioactive metal, wherein the composition has a pH of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg/mL ethanol; and 5-10 mg/mL sodium chloride.
A method for reconstructing medical images comprises: identifying a plurality of organs in a body of a subject based on an anatomic image; assigning a plurality of voxels in the body to respective ones of the plurality of organs based on the anatomic image; and reconstructing activity images of the body using respectively different processing for the voxels assigned to each respective one of the plurality of organs.
A compact radar system for detecting displacement of an internal organ of a patient in a medical scanner. The system includes at least one transmitting antenna and at least one receiving antenna located in a bed arrangement that supports the patient. In particular, the receiving antenna is located a predetermined distance from a patient reference location to enable detection of electromagnetic energy reflected from a region of the internal organ undergoing asymmetric displacement. The system further includes a radar energizing system that energizes the transmitting and receiving antennas wherein the transmitting antenna irradiates a volume of the patient's body that includes the internal organ. In addition, the receiving antenna detects the reflected electromagnetic energy from the region of the internal organ undergoing asymmetric displacement to enable determination of inhalation and exhalation by the patient.
G01S 13/58 - Systèmes de détermination de la vitesse ou de la trajectoire; Systèmes de détermination du sens d'un mouvement
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
G01S 7/35 - DÉTERMINATION DE LA DIRECTION PAR RADIO; RADIO-NAVIGATION; DÉTERMINATION DE LA DISTANCE OU DE LA VITESSE EN UTILISANT DES ONDES RADIO; LOCALISATION OU DÉTECTION DE LA PRÉSENCE EN UTILISANT LA RÉFLEXION OU LA RERADIATION D'ONDES RADIO; DISPOSITIONS ANALOGUES UTILISANT D'AUTRES ONDES - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe - Détails de systèmes non impulsionnels
G01S 13/86 - Combinaisons de systèmes radar avec des systèmes autres que radar, p.ex. sonar, chercheur de direction
G01S 13/88 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques
5.
METHOD AND SYSTEM FOR DETERMINING TUMOR BURDEN IN MEDICAL IMAGES
A method and system for determining system-based tumor burden is disclosed. In one aspect of the invention, the method includes obtaining the medical image from a source, through an interface. Additionally, the method includes identifying a first region of interest in the medical image. The method also includes selecting from the first region of interest a second region of interest whose tumor burden is to be determined. Furthermore, the method includes defining a segmentation criterion for the second region of interest. The method also includes determining the tumor burden for the second region of interest.
Embodiments provide a computer-implemented method of deriving a periodic motion signal from imaging data for continuous bed motion acquisition, including: acquiring a time series of three dimensional image volumes; estimating a first motion signal through a measurement of distribution of each three dimensional image volume; dividing the time-series of three dimensional image volumes into a plurality of axial sections overlapping each other by a predetermined amount; performing a spectral analysis on each axial section to locate a plurality of three dimensional image volumes which are subject to a periodic motion; performing a phase optimization on each axial section to obtain a three dimensional mask; estimating a second motion signal through the three dimensional mask and the time-series of three dimensional image volumes; and estimating a final motion signal based on the first motion signal and the second motion signal.
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
A61B 5/113 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre se produisant au cours de la respiration
For dose calibration (39) in functional imaging, different precision sources (22, 25) for a same long-lived isotope are used to calibrate, avoiding having to ship one source from one location to another location. A ratio of sensitivities of a gas ion chamber- based dose calibrator (20) at a reference laboratory to the precision source (22) of the long-lived isotope to a source (23) with an isotope to be used for imaging is found. At the clinical site (e.g., radio-pharmacy or functional imaging facility), a measure (34) of the sensitivity of a local gas ion chamber-based dose calibrator (24) to the other source (25) with the long-lived isotope and the ratio from the remote gas ion chamber-based dose calibrator (20) are used to determine sensitivity of the local gas ion chamber-based dose calibrator (24) to the isotope of the radiopharmaceutical (26). The bias and corresponding dose for the radiopharmaceutical (26) to be used for imaging a patient are based on activity for the radiopharmaceutical (26) as calibrated to account for the sensitivity of the local gas ion chamber-based dose calibrator (24) to the isotope of the radiopharmaceutical (26).
For dose calibration in functional imaging, different precision sources for a same long-lived isotope are used to calibrate, avoiding having to ship one source from one location to another location. A ratio of sensitivities of a gas ion chamber-based dose calibrator at a reference laboratory to the precision source of the long-lived isotope to a source with an isotope to be used for imaging is found. At the clinical site, a measure of the sensitivity of a local gas ion chamber-based dose calibrator to the other source with the long lived isotope and the ratio from the remote gas ion chamber-based dose calibrator are used to determine sensitivity of the local gas ion chamber based dose calibrator to the isotope of the radiopharmaceutical. The bias and corresponding dose for the radiopharmaceutical to be used for imaging a patient are based on activity for the radiopharmaceutical as calibrated.
For dose calibration (39) in functional imaging, different precision sources (22, 25) for a same long-lived isotope are used to calibrate, avoiding having to ship one source from one location to another location. A ratio of sensitivities of a gas ion chamber- based dose calibrator (20) at a reference laboratory to the precision source (22) of the long-lived isotope to a source (23) with an isotope to be used for imaging is found. At the clinical site (e.g., radio-pharmacy or functional imaging facility), a measure (34) of the sensitivity of a local gas ion chamber-based dose calibrator (24) to the other source (25) with the long-lived isotope and the ratio from the remote gas ion chamber-based dose calibrator (20) are used to determine sensitivity of the local gas ion chamber-based dose calibrator (24) to the isotope of the radiopharmaceutical (26). The bias and corresponding dose for the radiopharmaceutical (26) to be used for imaging a patient are based on activity for the radiopharmaceutical (26) as calibrated to account for the sensitivity of the local gas ion chamber-based dose calibrator (24) to the isotope of the radiopharmaceutical (26).
Embodiments can provide a medical imaging patient bed with an integrated electronic ruler system, comprising a light strip, mounted to the medical imaging bed; a trough comprising an open end and a closed end, mounted to the medical imaging bed and oriented such that the light strip is bounded by the open end and the closed end of the trough; a laser distance meter attached to the open end of the trough; a microcontroller; and a power source configured to provide power to the light strip, laser distance meter, and microcontroller; wherein the microcontroller is configured to illuminate the light strip after one or more distance measurements are received from the laser distance meter when an object is inserted into the trough; wherein a position of the illumination of the light strip corresponds to the one or more distance measurements received from the laser distance meter.
A61B 6/04 - Mise en position des patients; Lits inclinables ou similaires
A61G 7/05 - Lits spécialement conçus pour donner des soins; Dispositifs pour soulever les malades ou les personnes handicapées - Parties constitutives, détails ou accessoires de lits
G01B 11/02 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer la longueur, la largeur ou l'épaisseur
G01B 17/00 - Dispositions pour la mesure caractérisées par l'utilisation de vibrations infrasonores, sonores ou ultrasonores
11.
NORMALIZATION CRYSTAL EFFICIENCIES ESTIMATION FOR CONTINUOUS MOTION BED ACQUISITION
A method and system for simultaneously monitoring a positron emission tomography scanner performance during a continuous-bed-motion acquisition is disclosed.
A method of processing and reconstructing dynamic positron emission tomography (PET) sinogram data comprises: acquiring PET sinogram data using continuous bed motion having a varying velocity; recording a plurality of position-time coordinate pairs while acquiring the PET sinogram data; determining respective acquisition times of each of a plurality of slices of the image, based on the plurality of position-time coordinates; and reconstructing respective parametric images for each respective slice in the plurality of slices.
In one embodiment, a method includes forming a powder having a composition with the formula: A hBiCjO12, where h is 3 ~ 10%, i is 2 ~ 10%, j is 3 ~ 10%, A includes one or more rare earth elements, B includes aluminum and/or gallium, and C includes aluminum and/or gallium. The method additionally includes consolidating the powder to form an optically transparent ceramic, and applying at least one thermodynarnic process condition during the consolidating to reduce oxygen and/or thermodynamically reversible defects in the ceramic. ln another embodiment, a scintillator includes (Gd3-a-c Y a)x(Ga5- bAlb)yO12Dc, where a is from about 0.05-2, b is from about 1-3, x is from about 2.8-3.2, y is from about 4.8-5.2, c is from about 0.003-0.3, and D is a dopant, and where the scintillator is an optically transparent ceramic scintillator having physical characteristics of being formed from a ceramic powder consolidated in oxidizing atmospheres.
C04B 35/50 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de composés de terres rares
C09K 11/80 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares contenant de l'aluminium ou du gallium
In one embodiment, a method includes forming a powder having a composition with the formula: AhBiCjO12, where h is 3 ± 10%, i is 2 ± 10%, j is 3 ±10%, A includes one or more rare earth elements, B includes aluminum and/or gallium, and C includes aluminum and/or gallium. The method additionally includes consolidating the powder to form an optically transparent ceramic, and applying at least one thermodynamic process condition during the consolidating to reduce oxygen and/or thermodynamically reversible defects in the ceramic. In another embodiment, a scintillator includes (Gd3-a-cYa)x(Ga5-bAlb)yO12Dc, where a is from about 0.05-2, b is from about 1-3, x is from about 2.8-3.2, y is from about 4.8-5.2, c is from about 0.003-0.3, and D is a dopant, and where the scintillator is an optically transparent ceramic scintillator having physical characteristics of being formed from a ceramic powder consolidated in oxidizing atmospheres.
C04B 35/626 - Préparation ou traitement des poudres individuellement ou par fournées
C04B 35/50 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de composés de terres rares
C09K 11/80 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares contenant de l'aluminium ou du gallium
A sealed flexible pouch having an aseptic interior, the sealed flexible pouch including a container for holding a pharmaceutical solution, one or more additional components, and a template frame, wherein the container and the one or more additional components are affixed to a template frame in a predetermined first arrangement and provided inside the sealed flexible pouch.
A61J 1/20 - Dispositions pour le transfert des liquides, p.ex. du flacon à la seringue
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p.ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
A method of making LSO scintillators with high light yield and short decay times is disclosed. In one arrangement, the method includes codoping LSO with cerium and another dopant from the IIA or IIB group of the periodic table of elements. The doping levels are chosen to tune the decay time of scintillation pulse within a broader range (between about - 30 ns up to about - 50 ns) than reported in the literature, with improved light yield and uniformity. In another arrangement, relative concentrations of dopants are chosen to achieve the desired light yield and decay time while ensuring crystal growth stability.
A method for synthesizing an 18F-labeled probe. The method includes a step of eluting an amount of 18F with a first solvent which includes a predetermined amount of water and at least one organic solvent. In this step, the 18F elutes as an 18F solution. The method also includes a step of using the 18F solution to perform 18F-labeling in the presence of at least one labeling reagent and at least one phase transfer catalyst so as to generate the 18F-labeled probe. In the method, there is no step of drying the 18F starting from a time when the eluting step is performed and ending at a time when the 18F-labeling step is performed.
G01N 33/534 - Production de composés immunochimiques marqués avec un marqueur radioactif
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
B01D 15/36 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p.ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT)
The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
The present application is directed to radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
APD-based PET modules are provided for use in combined PET/MR imaging. Each module includes a number of independent, optically isolated detectors. Each detector includes an array of scintillator (e.g LSO) crystals read out by an array of APDs. The modules are positioned in the tunnel of a MR scanner. Simultaneous, artifact-free images can be acquired with the APD-based PET and MR system resulting in a high-resolution and cost-effective integrated PET/MR system
brevets
